Company intelligence / Profile preview

Pelagia

Bergen, Vestland, Norwaypelagia.com ↗

Ownership: Private
Employees: ~1200
Development stage: Commercial

Overview

Pelagia’s Health division through Epax Norway AS produces highly concentrated marine omega oils for use as dietary supplements and pharmaceutical ingredients. The company has invested in new synthesis/fractionation technology to develop next-generation products including patented forms of Omega‑9 and Omega‑11 for nutraceutical applications targeting skin and metabolic health. No clinical trial results are reported directly by the company; their products are used as ingredients in commercialized supplements or pharma preparations.

Therapeutic areas: Metabolic DisordersCardiovascularDermatology
Modalities: Fish oil concentrate (Omega fatty acids)Dietary supplement ingredientPharmaceutical ingredient
Industry: Food & Nutrition

Partnerships

Alfa Laval for equipment/process optimization

Beyond the preview

Go deeper on Pelagia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelagia.

Explore the full profile